美国贸易代表贾米森·格里尔在达沃斯表示，特朗普因其收购格陵兰的计划而威胁对欧洲部分国家加征 关税，这是恰当的做法。 "我认为这是合理使用关税，"他说。 格里尔表示，这属于在经济与国家安全的"交汇点"上将关税作为工具的范畴。 美国贸易代表贾米森·格里尔在达沃斯表示，特朗普因其收购格陵兰的计划而威胁对欧洲部分国家加征 关税，这是恰当的做法。 "我认为这是合理使用关税，"他说。 格里尔表示，这属于在经济与国家安全的"交汇点"上将关税作为工具的范畴。 责任编辑：李桐 责任编辑：李桐 ...

Core Points - The Trump administration has confirmed it does not plan to impose tariffs on foreign generic drugs, which account for approximately 90% of the medications used by Americans daily [1][2] - This decision marks a significant reduction in the scope of the Department of Commerce's investigation under the "Section 232" national security framework regarding pharmaceutical products [2] - There are internal divisions within the government regarding the imposition of tariffs on generic drugs, with some officials warning that such tariffs could lead to increased consumer costs and potential drug shortages [3][4] Group 1 - The decision to exclude generic drugs from tariff lists is a reversal of previous commitments made by Trump to bring essential drug production back to the U.S. [2] - The administration is still pursuing the goal of "manufacturing return," considering federal funding or loans for domestic manufacturers of critical generic drugs [1][2] - The potential use of funds from foreign governments, such as Japan, as part of tariff agreements is under consideration, although infrastructure funding has not yet been established [1] Group 2 - Some officials argue that high tariffs on generic drugs may not make domestic production profitable due to the low production costs in countries like India, which supplies nearly half of U.S. generic drugs [3] - Conversely, protectionist officials believe that reliance on foreign suppliers poses a national security risk and that tariffs could incentivize domestic production [3] - The government is adopting a detailed approach to reshape the generic drug manufacturing landscape to avoid supply chain disruptions experienced during the COVID-19 pandemic [3]